Prophylaxis Against Recurrent Hepatitis B Virus Infection after Liver Transplantation

摘要

Over the past two decades, there have been significant improvements in the outcomes of liver transplantation for all indications. Liver transplantation for hepatitis B virus (HBV) infection, once considered a contraindication to transplantation, now achieves survival rates of 91% at 1 year, 81% at 5 years, and 73% at 10 years. This improvement in outcome has occurred largely with the introduction of therapies that prevent, reinfection of the hepatic allograft and thus recurrent hepatitis B, cirrhosis, and graft failure. In the United States, it is estimated that 1.25 million people are chronically infected with HBV, resulting in approximately 5000 liver-related deaths and 250 liver transplantations annually. This review summarizes the important accomplishments in the successful application of liver transplantation for liver disease related to HBV infection.